^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    ABBV-101

    i
    Other names: ABBV-101
    Company:
    AbbVie
    Drug class:
    BTK degrader
    Related drugs:
    5ms
    M23-647: Study to Evaluate Adverse Events, Change in Disease Activity, and How Oral ABBV-101 Moves Through the Body in Adult Participants With B-Cell Malignancies (clinicaltrials.gov)
    P1, N=128, Recruiting, AbbVie | Trial completion date: Jun 2027 --> Apr 2029
    Trial completion date • Adverse events
    |
    ALK (Anaplastic lymphoma kinase) • BCL2 (B-cell CLL/lymphoma 2) • BCL6 (B-cell CLL/lymphoma 6)
    |
    ABBV-101
    10ms
    M23-647: Study to Evaluate Adverse Events, Change in Disease Activity, and How Oral ABBV-101 Moves Through the Body in Adult Participants With B-Cell Malignancies (clinicaltrials.gov)
    P1, N=128, Recruiting, AbbVie | N=188 --> 128
    Enrollment change • Adverse events
    |
    ALK (Anaplastic lymphoma kinase) • BCL2 (B-cell CLL/lymphoma 2) • BCL6 (B-cell CLL/lymphoma 6)
    |
    ALK positive • BCL6 rearrangement • BCL2 rearrangement
    |
    ABBV-101
    1year
    Abbv-101, a Highly Potent and Selective Clinical Stage Bruton Tyrosine Kinase Degrader for the Treatment of B-Cell Malignancies (ASH 2023)
    ABBV-101 is currently in phase 1 clinical trial for a variety of B-cell malignancies. ClinicalTrials.gov identifier: NCT05753501
    Clinical • IO biomarker
    |
    BTK (Bruton Tyrosine Kinase)
    |
    BTK C481S • BTK mutation
    |
    ABBV-101
    over1year
    Study to Evaluate Adverse Events, Change in Disease Activity, and How Oral ABBV-101 Moves Through the Body in Adult Participants With B-Cell Malignancies (clinicaltrials.gov)
    P1, N=188, Recruiting, AbbVie | N=128 --> 188
    Enrollment change • Adverse events
    |
    ALK (Anaplastic lymphoma kinase) • BCL2 (B-cell CLL/lymphoma 2) • BCL6 (B-cell CLL/lymphoma 6)
    |
    ALK positive • BCL6 rearrangement • BCL2 rearrangement
    |
    ABBV-101
    over1year
    Study to Evaluate Adverse Events, Change in Disease Activity, and How Oral ABBV-101 Moves Through the Body in Adult Participants With B-Cell Malignancies (clinicaltrials.gov)
    P1, N=128, Recruiting, AbbVie | Not yet recruiting --> Recruiting
    Enrollment open • Adverse events
    |
    ALK (Anaplastic lymphoma kinase) • BCL2 (B-cell CLL/lymphoma 2) • BCL6 (B-cell CLL/lymphoma 6)
    |
    ALK positive • BCL6 rearrangement • BCL2 rearrangement
    |
    ABBV-101
    over1year
    Study to Evaluate Adverse Events, Change in Disease Activity, and How Oral ABBV-101 Moves Through the Body in Adult Participants With B-Cell Malignancies (clinicaltrials.gov)
    P1, N=128, Not yet recruiting, AbbVie
    New P1 trial • Adverse events
    |
    ALK (Anaplastic lymphoma kinase) • BCL2 (B-cell CLL/lymphoma 2) • BCL6 (B-cell CLL/lymphoma 6)
    |
    ALK positive • BCL6 rearrangement • BCL2 rearrangement
    |
    ABBV-101